Last reviewed · How we verify
Fluticasone propionate HFA 220
At a glance
| Generic name | Fluticasone propionate HFA 220 |
|---|---|
| Also known as | Corticosteroid |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes (NA)
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS) (PHASE2)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- Biomarkers of Irritant-Induced and Allergic Asthma (PHASE2)
- DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone propionate HFA 220 CI brief — competitive landscape report
- Fluticasone propionate HFA 220 updates RSS · CI watch RSS
- NYU Langone Health portfolio CI